iotrolan has been researched along with Nervous System Disorders in 1 studies
iotrolan: nonionic, isotonic contrast medium designed for intrathecal use; RN given refers to cpd without isomeric designation; DL-3-117 refers to stereoisomer; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metrizamide neurotoxicity has been hypothesized to be caused by an inhibitory effect of the drug on glucose metabolism." | 1.27 | Further support for the glucose hypothesis of metrizamide toxicity. The effect of metrizamide and glucose analogue-free contrast media on hexokinase. ( Ekholm, SE; Fonte, DJ; Morris, TW; Simon, JH, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simon, JH | 1 |
| Ekholm, SE | 1 |
| Morris, TW | 1 |
| Fonte, DJ | 1 |
1 other study available for iotrolan and Nervous System Disorders
| Article | Year |
|---|---|
Further support for the glucose hypothesis of metrizamide toxicity. The effect of metrizamide and glucose analogue-free contrast media on hexokinase.
Topics: Contrast Media; Diatrizoate Meglumine; Glucose; Hexokinase; Iohexol; Iopamidol; Metrizamide; Nervous | 1987 |